Treatment
Specific treatment for sHLH was administrated to patients. Of 32 cases
in 25-(OH)-D <30nmol/L, 24 patients (75%) received HLH-94 or
HLH-04 orsystemic combination chemotherapy like EPOCH, CHOP, DEP; 6
patients (18.8%) received GC± Ivig ± CsA alone; and 2 patients (6.3%)
received only supportive therapy due to progressive multiple organ
dysfunction or patients’ aspiration. Among 22 (40.7%) patients with
25-(OH)-D≥30nmol/L, 18 (81.8%) were treated with chemotherapy or
HLH-94/04; 3 (13.6%) were treated with GC± Ivig ± CsA alone; and 1
patient (4.5%) was administrated with supportive therapy. No
statistically significant difference was observed in treatment regimen
between two 25-(OH)-D groups (P =0.839).